Literature DB >> 24113067

Changing epidemiology of candidemia in a medical center in middle Taiwan.

Ing-Moi Hii1, Hui-Lan Chang2, Li-Chen Lin2, Yu-Lin Lee1, Yuag-Meng Liu1, Chun-Eng Liu1, Chang-Hua Chen1, Yu-Ren Cheng1, Chih-Yen Chang3.   

Abstract

BACKGROUND: Candidemia remains a major cause of morbidity and mortality in the health care setting, and the epidemiology of Candida infection is changing.
METHODS: Clinical and laboratory data from patients with candidemia were collected retrospectively at a tertiary medical center in Taiwan from July 1, 2009 to June 30, 2012 (a 36-month period). Demographics, clinical characteristics, and drug susceptibility of the invading Candida species of patients at the onset of candidemia were analyzed and compared with previous study from January 1, 2001 to June 30, 2003 (a 30-month period).
RESULTS: A total of 209 episodes of candidemia in 205 patients were identified in this study period. When compared with the previous study period, more patients were admitted for medical conditions at percentages ranging from 49.5% to 69.8%; the incidence rate of health care-associated candidemia increased from 0.76 to 1.14 per 1000 discharges; the proportion of Candida albicans in patients with candidemia decreased from 64.8% to 43.6% whereas the proportion of Candida glabrata increased greatly from 1.1% to 21.6% and the proportions of Candida tropicalis and Candida parapsilosis were slightly elevated (19.8-22.0% and 2.2-7.3%, respectively). All of the C. albicans isolates remained susceptible to fluconazole, whereas 66.7% of C. glabrata isolates were dose-dependent susceptible, and 4.4% of C. glabrata isolates and 11.6% C. tropicalis isolates were resistant. There was one C. glabrata and one Candida guilliermondii resistant to echinocandin. The predictors for 30-day mortality included the high Acute Physiology and Chronic Health Evaluation II (APACHE II) score, use of parenteral nutrition, underlying malignancy, liver cirrhosis, and neutropenia whereas candidemia by C. parapsilosis or C. glabrata is a favorable predictor when compared with C. albicans.
CONCLUSION: The distribution of Candida species in candidemia was changed. Although C. albicans remained the major species, the isolation of non-C. albicans spp., especially C. glabrata, increased. Patients with candidemia still had high mortalities due to severity of illness and underlying conditions.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Antifungal susceptibility; Candida species; Candidemia

Mesh:

Substances:

Year:  2013        PMID: 24113067     DOI: 10.1016/j.jmii.2013.08.017

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  14 in total

1.  A prediction rule for early recognition of patients with candidemia in Internal Medicine: results from an Italian, multicentric, case-control study.

Authors:  Emanuela Sozio; Filippo Pieralli; Anna Maria Azzini; Giancarlo Tintori; Federica Demma; Gianluca Furneri; Francesco Sbrana; Giacomo Bertolino; Simona Fortunato; Simone Meini; Damiano Bragantini; Alessandro Morettini; Carlo Nozzoli; Francesco Menichetti; Ercole Concia; Carlo Tascini
Journal:  Infection       Date:  2018-06-09       Impact factor: 3.553

Review 2.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

3.  Echinocandins versus Amphotericin B Against Candida tropicalis Fungemia in Adult Hematological Patients with Neutropenia: A Multicenter Retrospective Cohort Study.

Authors:  Liangshun You; Cunying Yao; Fan Yang; Qing Yang; Jianping Lan; Xiaolu Song; Jianping Shen; Xianfu Sheng; Xiaohui Chen; Huifen Tang; Huifang Jiang; Haiying Wu; Shenxian Qian; Haitao Meng
Journal:  Infect Drug Resist       Date:  2020-07-10       Impact factor: 4.003

4.  Candidemia due to Candida guilliermondii in an immuno-compromised infant: a case report and review of literature.

Authors:  Fatemeh Ahangarkani; Hamid Badali; Mohammad Sadegh Rezai; Tahereh Shokohi; Zahra Abtahian; Hassan Mahmoodi Nesheli; Hossein Karami; Emmanuel Roilides; Ahmad Tamaddoni
Journal:  Curr Med Mycol       Date:  2019-03

5.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance.

Authors:  Lisa R McTaggart; Ana Cabrera; Kirby Cronin; Julianne V Kus
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Oligonucleotide Array and VITEK Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Species Identification of Blood Yeast Isolates.

Authors:  Ming-Chi Li; Tsung C Chang; Hung-Mo Chen; Chi-Jung Wu; Shu-Li Su; Susan S-J Lee; Po-Lin Chen; Nan-Yao Lee; Ching-Chi Lee; Chia-Wen Li; Ling-Shan Syue; Wen-Chien Ko
Journal:  Front Microbiol       Date:  2018-01-26       Impact factor: 5.640

Review 7.  Candida auris: Disinfectants and Implications for Infection Control.

Authors:  Tsun S N Ku; Carla J Walraven; Samuel A Lee
Journal:  Front Microbiol       Date:  2018-04-12       Impact factor: 5.640

8.  Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.

Authors:  Michael A Pfaller; Daniel J Diekema; John D Turnidge; Mariana Castanheira; Ronald N Jones
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

Review 9.  Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision.

Authors:  Felix Bongomin; Sara Gago; Rita O Oladele; David W Denning
Journal:  J Fungi (Basel)       Date:  2017-10-18

10.  Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients.

Authors:  Ping-Feng Wu; Wei-Lun Liu; Min-Han Hsieh; Ing-Moi Hii; Yu-Lin Lee; Yi-Tsung Lin; Mao-Wang Ho; Chun-Eng Liu; Yen-Hsu Chen; Fu-Der Wang
Journal:  Emerg Microbes Infect       Date:  2017-10-11       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.